Benjamin Adams is a Content Editor at Forbes. He focuses on psychedelic research, therapy, and the cannabis industry, including cannabidiol (CBD) and cannabis regulation. Benjamin's work has been featured in Forbes, NewsBreak, and arXiv.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Benjamin's coverage predominantly focuses on the health aspects of cannabis and psychedelics, with an emphasis on expert commentary and data-backed analysis. He appears to be particularly interested in studies, market trends, and regulatory developments related to these substances.
Given Benjamin’s focus on expert commentary and data citations, he is likely to respond well to pitches that offer insights from credible experts in the fields of cannabis research, healthcare professionals specializing in alternative medicine or drug policy reform advocates. Pitches supported by recent relevant data or studies are also likely to resonate with him.
While there is no specific geographic focus mentioned for Benjamin's coverage, his articles do occasionally reference specific locations such as Connecticut and Las Vegas; therefore, if pitching a location-specific story it may be beneficial to align with those references when relevant.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Ghana’s Narcotics Control Commission (NACOC) issued a warning Monday, clarifying that no one is yet authorized to issue cannabis licenses and charge applicants for it.
and co-founder of Weedmaps. Weed.de was recently unveiled as Germany's latest digital platform that aims to connect patients, doctors, pharmacies, and CBD shops. On Monday, the platform announced its plans to expand into the country, with new leadership roles.
A new study suggests that combining hyperspectral imaging (HSI) with machine learning is the key to predicting cannabinoid content—weeks in advance—with high accuracy. This technique would enable growers to accurately predict the final cannabinoid content in plants still in the early and later flowering stages, long before harvest, allowing them to appraise cannabis early.
A dual cannabinoid agonist drug candidate is being investigated for its potential in treating wasting syndrome in cancer patients. It demonstrated a weight gain in patients who took the drug versus a weight decrease in those who took a placebo.
A stunning portrayal of heroes and advocates in the form of an art series was recently unveiled, showcasing a 120-foot mural in Miami.
Ahead of the Halloween holiday this year, officials in multiple states issued warnings to parents to check trick-or-treater candy for cannabis-laced candy.
This weekend, scientists, lawyers, and experts are gathering to discuss the future of psychedelic-assisted therapy and medical cannabis in the future of medicine.
The U.S. hemp industry is abuzz about a looming ban on hemp-derived compounds. By banning hemp-derived THC products, the U.S. government is also
The state of New York's first licensed adult-use cannabis dispensary is honoring World AIDS Day on Dec. 1, and every dollar you spend there—on any
At the height of the meme stock craze, investors made and lost fortunes as their speculative trades made headlines. This trend was so dramatic and so widespread that reporting on it moved beyond financial publications into the mainstream press and even into a few movie scripts.
